Overview
VANI market data
Price History
VANI price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.42 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.40 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.92 – $1.92 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $113 · P/B 5.70 · P/S 33.42.
Company News
8-K filing — Vivani Medical, Inc. (VANI)SEC EDGAR · Jul 16, 2026, 12:30 PM
Presenting on Emerging Growth Conference 94 Day 1 on July 15; Register to live streamGlobenewswire Inc · Jul 14, 2026, 11:15 AM
Vivani Medical To Allow Novo Nordisk To Evaluate NPM-139, The Company’s Semaglutide Drug ImplantBenzinga · Jul 7, 2026, 11:45 AM
Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.Globenewswire Inc · Jul 2, 2026, 12:15 PM
ClearOne To Acquire Vivani Medical Subsidiary Cortigent For 12.5M Shares Of CLRO Worth ~$40.4M; ClearOne To File S-1 Seeking To Raise $10M-$15MBenzinga · Jul 2, 2026, 12:10 PM
Vivani Medical Receives Approval From Australian Human Research Ethics Committee Bellberry To Initiate SLIM-1, A Phase 1 Clinical Trial Of Semaglutide Implant NPM-139Benzinga · Jun 25, 2026, 11:40 AM
Lake Street Initiates Coverage On Vivani Medical with Buy Rating, Announces Price Target of $4Benzinga · Jun 23, 2026, 2:30 PM